A study published in Nature Medicine has found that changes in the gut microbiome may signal proximity to Parkinson’s disease years before symptoms appear, offering a potential early detection tool.
Researchers analyzed fecal metagenomics data from 464 individuals, including 271 diagnosed Parkinson’s patients, 43 non-manifesting GBA1 variant carriers, and 150 healthy controls.
They identified that over 25% of the gut microbiome in at-risk individuals exists in an intermediate state between healthy and diseased states, mirroring patterns seen in confirmed Parkinson’s cases.
This microbial signature was replicated across three independent international cohorts from the United States, Korea, and Turkey, involving a total of 638 Parkinson’s patients and 319 healthy controls.
The study focused on GBA1 gene variants, the most common genetic risk factor for Parkinson’s, which increase disease risk up to 30-fold, though only about 20% of carriers develop the condition.
Among non-manifesting GBA1 carriers, researchers observed worse motor symptoms and higher scores on non-motor symptom scales, including cognitive impairment and urinary issues, suggesting a prodromal phase.
Within this group, 10 individuals met estimated probability thresholds for prodromal Parkinson’s based on available clinical criteria.
More than half of the healthy control participants were partners of people with Parkinson’s, a design choice intended to minimize lifestyle and dietary influences on microbiome comparisons.
The abundance of more than a quarter of gut microbes — or 176 species — differed between Parkinson’s patients and healthy individuals, with changes not driven by medication.
For more on this story, see Gut-Liver Axis: Microbiome’s Role in Liver Disease and Risks.
A similar pattern of microbial alteration was seen in genetically predisposed individuals who remained asymptomatic, indicating the signature appears prior to clinical diagnosis.
Prof Anthony Schapira of University College London, lead investigator on the study, stated this is the first time a microbial signature seen in Parkinson’s patients has been detected in genetically susceptible individuals without symptoms.
He noted the signature strengthens as disease progresses and may be present in a tiny proportion of the general population, suggesting broader risk implications.
Schapira added that microbiome changes could influence alpha-synuclein production, a protein central to neuronal damage in Parkinson’s, though it remains unclear whether microbial shifts drive the disease or result from it.
The researchers emphasized that while the findings suggest the microbiome may serve as an early marker of disease proximity, they do not yet establish a clinically validated predictor of future Parkinson’s.
With Parkinson’s prevalence more than doubling over the past 25 years to over 8.5 million globally, the require for pre-symptomatic detection tools has grown urgent, as dopaminergic loss often exceeds 50% by clinical diagnosis.
This follows our earlier report, Gut Health and Dementia: Early Detection and Prevention.
What specific microbiome changes were linked to Parkinson’s risk in the study?
Over 25% of the gut microbiome in at-risk individuals showed an intermediate abundance pattern between healthy and diseased states, involving alterations in 176 microbial species not driven by medication.
How did researchers confirm the microbiome findings were not coincidental?
>They replicated the microbial signature across three independent international cohorts from the US, Korea, and Turkey, totaling 638 Parkinson’s patients and 319 healthy controls.
Why focus on people with GBA1 gene variants who don’t yet have symptoms?
Since GBA1 variants increase Parkinson’s risk up to 30-fold, yet only about 20% of carriers develop the disease, making this group ideal for studying early biomarkers of disease progression.
Could altering the gut microbiome prevent or delay Parkinson’s disease?
The researchers suggest healthier diets and microbiome-reshape therapies might prevent or delay Parkinson’s, but they did not test interventions in this study and caution that causality remains unproven.